Search | Clinical Trials Finder

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: vatreptacog alfa (activated), eptacog alfa (activated); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 14
States / cities: Tucson, Arizona • Los Angeles, California • Orange, California + 10 more

Conditions: Hemophilia A With Inhibitors
Interventions: recombinant activated factor VII; Drug
Lead sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico; Other
Eligibility: Up to 8 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Los Angeles, California • Atlanta, Georgia • Kansas City, Missouri

Conditions: Acquired Bleeding Disorder, Bleeding During/Following Surgery
Interventions: standard therapy, activated recombinant human factor VII, placebo; Procedure · Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Acquired Bleeding Disorder, Trauma
Interventions: activated recombinant human factor VII; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 42
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 37 more

Conditions: Hemophilia A
Interventions: Factor IX; Drug
Lead sponsor: Tulane University; Other
Eligibility: 12 Years to 120 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Metairie, Louisiana • New Orleans, Louisiana

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: eptacog alfa (activated); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 4
States / cities: Berkeley, California • Los Angeles, California • Iowa City, Iowa + 1 more

Conditions: Haemostasis, Healthy
Interventions: warfarin, eptacog alfa (activated), placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Intracerebral Hemorrhage
Interventions: recombinant activated factor VII, placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 80 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 8
States / cities: Phoenix, Arizona • San Diego, California • Boston, Massachusetts + 5 more

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: activated recombinant human factor VII, Feiba VH; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Plainsboro, New Jersey

Conditions: Congenital Bleeding Disorder, Glanzmann's Disease
Interventions: activated recombinant human factor VII; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Not listed
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: activated recombinant human factor VII, factor IX, factor VIII; Drug · Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 5 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 14
States / cities: Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 9 more

Conditions: Acquired Bleeding Disorder, Bleeding During/Following Surgery
Interventions: standard therapy, placebo, activated recombinant human factor VII; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 7
States / cities: Little Rock, Arkansas • Duarte, California • Baltimore, Maryland + 4 more

Conditions: Hemophilia A
Interventions: Nuwiq, Octanate, Wilate, Emicizumab, Recombinant factor VIIa (rFVIIa), Activated prothrombin complex concentrate (aPCC); Biological
Lead sponsor: Emory University; Other
Eligibility: Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Cardiopulmonary Bypass
Interventions: Recombinant activated factor VII, Prothrombin Complex Concentrate; Drug
Lead sponsor: Emory University; Other
Eligibility: Up to 30 Days
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Other Haemostasis Disorder, Haemorrhagic Cystitis
Interventions: activated recombinant human factor VII; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 3
States / cities: Chapel Hill, North Carolina • Houston, Texas

Conditions: Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: eptacog alfa (activated), Feiba VH; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Up to 20 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 20
States / cities: Little Rock, Arkansas • Berkeley, California • Los Angeles, California + 16 more

Conditions: Acquired Bleeding Disorder, Trauma
Interventions: eptacog alfa (activated), placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Acquired Bleeding Disorder, Trauma
Interventions: activated recombinant human factor VII; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Plainsboro, New Jersey

Conditions: Thromboembolus, Massive Blood Transfusion; Thrombocytopenia, Trauma
Interventions: Number of Participants with massive blood transfusion; Procedure
Lead sponsor: Zeliha Alicikus; Government
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Jacksonville, Florida

Conditions: Congenital Bleeding Disorder, Haemophilia A, Haemophilia B
Interventions: eptacog alfa (activated), vatreptacog alfa (activated); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 12 Years and older · Male only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 12
States / cities: Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 9 more

Conditions: Haemostasis, Healthy
Interventions: eptacog alfa (activated), clopidogrel, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Hemophilia A, Hemophilia B
Interventions: BAY86-6150, eptacog alfa [activated]; Drug
Lead sponsor: Bayer; Industry
Eligibility: 12 Years to 62 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Sacramento, California • Chattanooga, Tennessee

Conditions: Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Interventions: MarzAA; Biological
Lead sponsor: Catalyst Biosciences; Industry
Eligibility: 12 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia

Conditions: Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass
Interventions: activated recombinant human factor VII; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 18
States / cities: Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 14 more

Search by objective public record fields.

Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors

rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma

Factor IX as Adjunctive Therapy to Emicizumab (EMIX)

Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography

Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment

The Spot Sign for Predicting and Treating ICH Growth Study

Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX

Observational Registry of the Treatment of Glanzmann's Thrombasthenia

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

Treatment of Hemophilia A Patients With FVIII Inhibitors

Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass

Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis

Trial of NovoSeven® in Haemophilia - Joint Bleeds

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding

Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury

Comparative Outcomes of PCC and Recombinant Activated Factor VIIa in Trauma-Associated Massive Transfusion

Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds

Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding

A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

Use of Activated Recombinant Human Factor VII in Cardiac Surgery